The Federal Trade Commission has approved a motion granting Chairman Andrew Ferguson the authority to comply with President Donald Trump’s executive orders slashing DEI programs.

U.S. Federal Trade Commission Chair Andrew Ferguson gained broad authority to purge diversity, equity and inclusion (DEI) policies at the agency after Democrats, who still have the majority on the commission,

Newsweek sought email comment from the FTC and its outgoing chairwoman, Lina Khan, on Friday. The flurry of lawsuits before the change to a GOP administration underscore the tension within the FTC between pro-regulation Democrats and anti-regulation Republicans.

Returning US President Donald Trump has made the art of the deal his trademark. The immediate future looks promising for the country’s M&A activity, with proponents welcoming his refreshing pro-business approach accompanied by less regulation.

New FTC Chair Andrew Ferguson is closing the agency’s Office of Workplace Inclusivity and Opportunity and placing all its employees on administrative leave, the agency said Wednesday.

Donald Trump vowed to slash grocery prices as soon as he took office, yet he has barely addressed the cost of food in the whirlwind of executive orders he signed in his first week.

Looking ahead, some analysts think the stock market will keep soaring as Trump pushes for deregulation and tax cuts during his second term. For instance, while on the campaign trail, he proposed lowering the corporate tax rate to 15% for domestic manufacturers. That could boost net profit margins and send the stock market higher.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two

Trump’s freeze on federal funds, fake buyout offers, and effort to fire inspector generals are about daring Democrats to try to stop him.

FTC shares tips to prevent identity theft

In recent decades, Republicans defined themselves as the party of free trade. Trump-era policies have challenged this position.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions of its drug — Semglee cost $269 and a generic version cost $99 for the same amount, according to the Biosimilars Council.